Drug intelligence / Profile preview

IS30YY

Development stage: Preclinical
Lead developer: iSeek Biopharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IS30YY is an investigational therapeutic radiopharmaceutical being developed by iSeek Biopharma for the treatment of hematological malignancies. It is designed to target the lymphocyte function-associated antigen 1 (LFA-1), a cell surface receptor predominantly expressed on leukocytes. The drug candidate consists of a targeting moiety specific to LFA-1 conjugated to a therapeutic radioisotope, intended to deliver localized ionizing radiation directly to malignant hematopoietic cells. Currently in the discovery stage, IS30YY represents the therapeutic application of iSeek's LFA-1-targeted radiopharmaceutical platform, which also includes diagnostic imaging agents like LEUKOPET™.

Targets

LFA-1 (Integrin αLβ2)

Beyond the preview

Go deeper on IS30YY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IS30YY.

Explore the full profile